Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Infection prevention products group Tristel nudged up its annual profit guidance after the rate of hospital admissions for non-Covid-related conditions began to recovery.
Pre-tax profit for the year through June, before exceptional items, was now expected at at £5.5 million, on revenue of $31 million.
That compared to previous guidance, given in April, of a pre-tax profit no less than £5 million, also on sales of £31 million.
'As the fourth quarter progressed, demand for the device-based products accelerated as hospital out-patient departments gradually returned to pre-pandemic levels of activity,' Tristel said.
'Surface disinfectant product sales have continued to grow.'
Tristel also announced that it would write off the value of an equity investment in a medical device company focussed upon women's health to the tune of £0.8 million.
The company had made the investment in 2017 and subsequently tried to find a buyer for its stake, but had not been successful selling it to date.